Utama › Tumor Neuroendokrin › Arizona
Kajian klinikal Tumor Neuroendokrin di Arizona
7 kajian untuk Tumor Neuroendokrin sedang mencari peserta di lokasi di Arizona.
Bandar di Arizona
Teks kajian rasmi (Bahasa Inggeris)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Mayo Clinic Hospital, Phoenix
- The University of Arizona Cancer Center, Tucson
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06943755Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
- Banner MD Anderson Cancer Center, Gilbert
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07087054Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Research Facility, Phoenix
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07165132Project: Every Child for Younger Patients With Cancer
- Kingman Regional Medical Center, Kingman
- Banner Children's at Desert, Mesa
- Phoenix Childrens Hospital, Phoenix
- dan 1 lagi
Mengambil pesertaKajian pemerhatian
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT02402244A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Phoenix
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT07129252Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Scottsdale Medical Imaging, LLC, Scottsdale
Mengambil pesertaFasa 4
Umur 18 hingga 64 · Semua jantina · Dikemas kini 22 Jan 2026 · NCT04373564SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scottsdale
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.